恩帕吉菲
医学
高钾血症
二羟基化合物
2型糖尿病
糖尿病
肾脏疾病
内科学
临床终点
心脏病学
重症监护医学
疾病
终点测定
梅德林
泌尿系统
风险评估
低风险
作者
Rajiv Agarwal,Jennifer B. Green,Hiddo J.L. Heerspink,Janet B. McGill,Amy K. Mottl,Masaomi Nangaku,Julio Rosenstock,Peter Rossing,Muthiah Vaduganathan,Carolina Solis‐Herrera,Charlie Scott,Li Li,Meike Brinke,Carolina Aldworth,Johannes F.E. Mann
标识
DOI：10.1016/j.jacc.2025.10.049
摘要
Over 180 days, the combination of empagliflozin and finerenone did not significantly mitigate the risk of hyperkalemia. The treatment effect was maintained regardless of development of hyperkalemia. (Combination Effect of Finerenone and Empagliflozin in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a Urinary Albumin-to-Creatinine Ratio Endpoint [CONFIDENCE]; NCT05254002).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
大力的冬萱
Avalonx
cdercder
ale
科研狗
weixia
arniu2008
潇洒的惋清
sagitar
行走的荷尔蒙
科研啦
OK
liuzhuohao
Copyright
卡乐瑞咩吹可
天晴
MozzieMiao
Oracle
昏睡的蟠桃
皖公网安备34019202002308
